Mazhar Adli

11.4k total citations · 4 hit papers
58 papers, 5.7k citations indexed

About

Mazhar Adli is a scholar working on Molecular Biology, Cancer Research and Reproductive Medicine. According to data from OpenAlex, Mazhar Adli has authored 58 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 10 papers in Cancer Research and 8 papers in Reproductive Medicine. Recurrent topics in Mazhar Adli's work include CRISPR and Genetic Engineering (16 papers), Genomics and Chromatin Dynamics (15 papers) and Epigenetics and DNA Methylation (11 papers). Mazhar Adli is often cited by papers focused on CRISPR and Genetic Engineering (16 papers), Genomics and Chromatin Dynamics (15 papers) and Epigenetics and DNA Methylation (11 papers). Mazhar Adli collaborates with scholars based in United States, Türkiye and Japan. Mazhar Adli's co-authors include Cem Kuscu, B Bernstein, Ritambhara Singh, Jeremy Thorpe, Şevki Arslan, Albert S. Baldwin, Manching Ku, Richard P. Koche, Carolyn Brokowski and Chad A. Cowan and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Mazhar Adli

56 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The CRISPR tool kit for genome editing and beyond

2018 1.1k citations Mazhar Adli Nature Communications profile →
Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains

2008 787 citations Manching Ku, Mazhar Adli et al. profile →
Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease

2014 609 citations Cem Kuscu, Mazhar Adli et al. profile →
Endometriosis and adenomyosis: shared pathophysiology

2023 88 citations Serdar E. Bulun, Şule Yıldız et al. Fertility and Sterility profile →

Peers

Countries citing papers authored by Mazhar Adli

Since Specialization

Citations

This map shows the geographic impact of Mazhar Adli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mazhar Adli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mazhar Adli more than expected).

Fields of papers citing papers by Mazhar Adli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mazhar Adli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mazhar Adli. The network helps show where Mazhar Adli may publish in the future.

Co-authorship network of co-authors of Mazhar Adli

This figure shows the co-authorship network connecting the top 25 collaborators of Mazhar Adli. A scholar is included among the top collaborators of Mazhar Adli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mazhar Adli. Mazhar Adli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic targeting of the tryptophan-kynurenine-aryl hydrocarbon receptor pathway with apigenin in MED12-mutant leiomyoma cells 2025 ·Cancer Gene Therapy ·Takashi Iizuka, (unknown), (unknown), John S. Coon, (unknown), (unknown), Mazhar Adli, Serdar E. Bulun, (unknown)	1
2	Depletion of lamins B1 and B2 promotes chromatin mobility and induces differential gene expression by a mesoscale-motion-dependent mechanism 2024 ·Genome biology ·(unknown), Xiaolong Wei, (unknown), Lucas Carter, Jiekun Yang, Luay M. Almassalha, Surbhi Jain, Ali Daneshkhah, Suhas S.P. Rao, Fidan Seker-Polat, Kyle L. MacQuarrie, (unknown), Vasundhara Agrawal, Erez Lieberman Aiden, Masato T. Kanemaki, Vadim Backman, Mazhar Adli	16
3	Single-nuclei sequencing of uterine serous carcinoma reveals racial differences in immune signaling 2024 ·Proceedings of the National Academy of Sciences ·(unknown), Mazhar Adli, (unknown)	1
4	Integrating leiomyoma genetics, epigenomics, and single-cell transcriptomics reveals causal genetic variants, genes, and cell types 2024 ·Nature Communications ·(unknown), (unknown), (unknown), Hoda Elkafas, Fidan Seker-Polat, Mazhar Adli	7
5	Adenomyosis: single-cell transcriptomic analysis reveals a paracrine mesenchymal–epithelial interaction involving the WNT/SFRP pathway 2023 ·Fertility and Sterility ·Şule Yıldız, (unknown), Jian Wei, Magdy P. Milad, Ping Yin, Mazhar Adli, Serdar E. Bulun	23
6	Endometriosis and adenomyosis: shared pathophysiology breakdown → 2023 ·Fertility and Sterility ·Serdar E. Bulun, Şule Yıldız, Mazhar Adli, Debabrata Chakravarti, (unknown), Magdy P. Milad, Linda Yang, Angela Chaudhari, Susan Tsai, Jian Wei, Ping Yin	88
7	Evolutionary Biology and Gene Editing of Cat Allergen, Fel d 1 2022 ·The CRISPR Journal ·(unknown), Brian W. Davis, Mazhar Adli, Anna Pomés, Martin D. Chapman	17
8	Tip60 acetylation of histone H3K4 temporally controls chromosome passenger complex localization 2022 ·Molecular Biology of the Cell ·E. Niedzialkowska, Limin Liu, Cem Kuscu, (unknown), W. Minor, Brian D. Strahl, Mazhar Adli, P. Todd Stukenberg	4
9	A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1 2021 ·Human Mutation ·Mourad W. Ali, (unknown), Matthew A.M. Devall, Christopher H. Dampier, Sarah J. Plummer, Cem Kuscu, Mazhar Adli, Rose Lai, Graham Casey	7
10	Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells 2020 ·Proceedings of the National Academy of Sciences ·Xiaolong Wei, Jiekun Yang, Sara J. Adair, (unknown), Cem Kuscu, Kyung Yong Lee, William J. Kane, (unknown), (unknown), (unknown), (unknown), (unknown), Anindya Dutta, Todd W. Bauer, Mazhar Adli	60
11	Ethical Considerations in Therapeutic Clinical Trials Involving Novel Human Germline-Editing Technology 2020 ·The CRISPR Journal ·Carolyn Brokowski, Mazhar Adli	6
12	Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer 2019 ·Cancer Research ·Stephen Shang, Jiekun Yang, Amir A. Jazaeri, (unknown), Turan Tufan, (unknown), Mouadh Benamar, Fadila Guessous, In-Young Lee, Robert M. Campbell, Philip J. Ebert, Tarek Abbas, Charles N. Landen, Analisa DiFeo, Peter C. Scacheri, Mazhar Adli	44
13	CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response 2018 ·Nature Communications ·Karol Szlachta, Cem Kuscu, Turan Tufan, Sara J. Adair, Stephen Shang, Alex D. Michaels, Matthew G. Mullen, (unknown), Jiekun Yang, Limin Liu, Prasad Trivedi, Edward B. Stelow, P. Todd Stukenberg, J. Thomas Parsons, Todd W. Bauer, Mazhar Adli	57
14	Super-enhancers maintain renin-expressing cell identity and memory to preserve multi-system homeostasis 2018 ·Journal of Clinical Investigation ·(unknown), (unknown), R. Brown, Turan Tufan, Stephen Shang, (unknown), (unknown), Mazhar Adli, Brian Belyea, Maria Luisa S. Sequeira-Lόpez, R. Ariel Gómez	34
15	The CRISPR tool kit for genome editing and beyond breakdown → 2018 ·Nature Communications ·Mazhar Adli	1101
16	Genome-wide Chromatin State Transitions Associated with Developmental and Environmental Cues 2013 ·Cell ·Jiang Zhu, Mazhar Adli, James Zou, (unknown), Michael J. Coyne, Xiaolan Zhang, Timothy Durham, Mohammad Reza Miri, Vikram Deshpande, Philip L. De Jager, David A. Bennett, Joseph A. Houmard, Deborah M. Muoio, Tamer T. Önder, (unknown), Chad A. Cowan, Alexander Meissner, Charles B. Epstein, Noam Shoresh, B Bernstein	380
17	Whole-genome chromatin profiling from limited numbers of cells using nano-ChIP-seq 2011 ·Nature Protocols ·Mazhar Adli, B Bernstein	131
18	Chromatin profiling by directly sequencing small quantities of immunoprecipitated DNA 2009 ·Nature Methods ·Alon Goren, Fatih Ozsolak, Noam Shoresh, Manching Ku, Mazhar Adli, Chris Hart, Melissa Gymrek, Or Zuk, Aviv Regev, Patrice M. Milos, B Bernstein	89
19	Regulation of Mammalian Target of Rapamycin Activity in PTEN-Inactive Prostate Cancer Cells by IκB Kinase α 2007 ·Cancer Research ·Han C. Dan, Mazhar Adli, Albert S. Baldwin	60
20	Resveratrol protects against 4‐HNE induced oxidative stress and apoptosis in Swiss 3T3 fibroblasts 2004 ·BioFactors ·Özgür Kütük, Mazhar Adli, Giuseppe Poli, Hüveyda Başağa	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact